Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

807.65
-2.6600-0.33%
Post-market: 807.650.00000.00%16:43 EDT
Volume:565.69K
Turnover:455.64M
Market Cap:83.15B
PE:19.97
High:808.63
Open:803.83
Low:796.73
Close:810.31
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:0.93
T/O Rate:0.57%
Dividend:3.64
Dividend Rate:0.45%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.62
PE(LYR):19.47

Loading ...

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Aug 27

Sector Update: Healthcare Stocks Edge Higher Premarket Tuesday

MT Newswires Live
·
Aug 25

Stick with Value Stocks Until Everyone Starts Talking About Them - and as of Now They're Still Under the Radar, This Wall Street Firm Says

Dow Jones
·
Aug 25

Veeva Systems Secures Biogen, Regeneron Pharmaceuticals as New Vault CRM Clients

MT Newswires Live
·
Aug 25

Regeneron Selects Veeva Vault CRM for Global Rollout

Reuters
·
Aug 25

Regeneron Pharmaceuticals (REGN) Wins Pasatru Approval, Is The Upside Already Priced In?

Simply Wall St.
·
Aug 22

Funds: What a Top Biotech Fund is Buying Now

Dow Jones
·
Aug 22

Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims

TIPRANKS
·
Aug 21

Sweden's Medivir Q2 Turnover Falls

Reuters
·
Aug 20

Telix Swings to H1 FY26 Net Profit of US$38 Million; Revenue Rises 22% to Us$477 Million

Reuters
·
Aug 20

Regeneron to Webcast Management Presentation at Wells Fargo Healthcare Conference

Reuters
·
Aug 20

Regeneron Announces Investor Conference Presentations

GlobeNewswire
·
Aug 20

Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition

MT Newswires Live
·
Aug 20

US FDA Approves Regeneron's Rare Bone Disorder Drug

Reuters
·
Aug 20

Regeneron Says FDA Approves Pasatru for Adults with Rare Bone Disorder FOP

Reuters
·
Aug 20

Regeneron Pharmaceuticals, - Pasatru Under Review by European Medicines Agency; Global Submissions Planned

THOMSON REUTERS
·
Aug 20

Regeneron Pharmaceuticals, - FDA Approves Pasatru (Garetosmab-Grts) for Adults with Fibrodysplasia Ossificans Progressiva

THOMSON REUTERS
·
Aug 20

Movement Alert|Regeneron Pharmaceuticals Rises 3.44% in Regular Trading, Investment Bank Sharply Raises Target Price Amid Biotech Sector Rally

Market Focus
·
Aug 19

What This Top Biotech Fund is Buying Now

Dow Jones
·
Aug 19

Regeneron Pharma Price Target Raised to $824.00/Share from $641.00 by Leerink Partners

Dow Jones
·
Aug 17